Insights

Innovative Oncology Therapies STipe Therapeutics is focused on pioneering immune-oncology therapies utilizing a unique aspect of the STING Pathway. This innovative approach presents sales opportunities for companies seeking cutting-edge cancer treatment solutions.

Expanded Leadership Team With the recent appointment of Dr. Richard Sainson as Chief Scientific Officer, STipe Therapeutics has strengthened its leadership team. This expansion signals growth potential for partnerships or collaborations, offering sales avenues for synergistic alliances.

Funding and Financial Stability Having secured $22 million in funding, STipe Therapeutics demonstrates financial stability and growth prospects. Businesses providing complementary services or products may find sales opportunities by engaging with a well-supported and expanding biotech company.

Strategic Industry Positioning STipe Therapeutics' focus on the biotechnology sector places it strategically within the healthcare industry. Sales professionals can explore partnerships with this well-positioned company to access a niche market and leverage mutual expertise for business growth.

Tech-Driven Solutions Utilizing technologies like Angular and TypeScript, STipe Therapeutics showcases a tech-savvy approach in its operations. Tech-oriented businesses looking to offer solutions or services can explore collaborations with STipe Therapeutics, creating potential sales channels in the biotech-tech interface.

STipe Therapeutics Tech Stack

STipe Therapeutics uses 2 technology products and services including Angular, TypeScript, and more. Explore STipe Therapeutics's tech stack below.

  • Angular
    Javascript Frameworks
  • TypeScript
    Programming Languages

STipe Therapeutics's Email Address Formats

STipe Therapeutics uses at least 1 format(s):
STipe Therapeutics Email FormatsExamplePercentage
FL@stipetherapeutics.comJD@stipetherapeutics.com
43%
First.Last@stipetherapeutics.comJohn.Doe@stipetherapeutics.com
28%
FLast@stipetherapeutics.comJDoe@stipetherapeutics.com
15%
LastF@stipetherapeutics.comDoeJ@stipetherapeutics.com
14%

Frequently Asked Questions

Where is STipe Therapeutics's headquarters located?

Minus sign iconPlus sign icon
STipe Therapeutics's main headquarters is located at Denmark, DK. The company has employees across 4 continents, including EuropeNorth AmericaAsia.

What is STipe Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
STipe Therapeutics's official website is stipetherapeutics.com and has social profiles on LinkedIn.

How much revenue does STipe Therapeutics generate?

Minus sign iconPlus sign icon
As of June 2024, STipe Therapeutics's annual revenue reached $1.8M.

What is STipe Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
STipe Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does STipe Therapeutics have currently?

Minus sign iconPlus sign icon
As of June 2024, STipe Therapeutics has approximately 22 employees across 4 continents, including EuropeNorth AmericaAsia. Key team members include President: B. S.Owner: J. S.Senior Research Scientist: J. U.. Explore STipe Therapeutics's employee directory with LeadIQ.

What industry does STipe Therapeutics belong to?

Minus sign iconPlus sign icon
STipe Therapeutics operates in the Biotechnology Research industry.

What technology does STipe Therapeutics use?

Minus sign iconPlus sign icon
STipe Therapeutics's tech stack includes AngularTypeScript.

What is STipe Therapeutics's email format?

Minus sign iconPlus sign icon
STipe Therapeutics's email format typically follows the pattern of . Find more STipe Therapeutics email formats with LeadIQ.

How much funding has STipe Therapeutics raised to date?

Minus sign iconPlus sign icon
As of June 2024, STipe Therapeutics has raised $22M in funding. The last funding round occurred on Sep 30, 2019 for $22M.

When was STipe Therapeutics founded?

Minus sign iconPlus sign icon
STipe Therapeutics was founded in 2018.
STipe Therapeutics

STipe Therapeutics

Biotechnology ResearchDenmark, Denmark11-50 Employees

STipe Therapeutics is a privately held biotechnology company with a vision to become a leader in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The Company was spun out from Aarhus University, Denmark in 2018 and concluded a EUR 20 million a Series A financing in September 2019.

JOB RECRUITMENT SCAM ALERT
STipe Therapeutics is aware of a job recruitment scam involving fraudulent human resources recruiters contacting job seekers. The scam includes requesting personal information, promising or requesting money to purchase office equipment, and interacting and conducting false interviews via social media platforms. Please note STipe Therapeutics does not utilize social media platforms to conduct formal job interviews or extend employment offers with job seekers. We encourage job seekers to be aware of this scam and remain vigilant while searching for a job with STipe Therapeutics.

Section iconCompany Overview

Headquarters
Denmark, DK
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $22M

    STipe Therapeutics has raised a total of $22M of funding over 2 rounds. Their latest funding round was raised on Sep 30, 2019 in the amount of $22M.

  • $10M

    STipe Therapeutics's revenue is in the range of $10M

Section iconFunding & Financials

  • $22M

    STipe Therapeutics has raised a total of $22M of funding over 2 rounds. Their latest funding round was raised on Sep 30, 2019 in the amount of $22M.

  • $10M

    STipe Therapeutics's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.